DDH
Conditions
Interventions
Reinfused group:intraoperative cell salvage
non-einfused group:control
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Between November 2010 and April 2022, data on consecutive patients who were diagnosed with Type-III or IV DDH according to Crowe classification and underwent cementless THA combined with SSO in our institution were retrospectively collected at West China Hospital.
Exclusion criteria
Exclusion criteria: The exclusion criteria comprised patients who (1) underwent THA combined with SSO due to high hip dislocation secondary to pyogenic arthritis; (2) underwent operative intervention for the purpose of treating DDH before THA combined with SSO (3) had dysfunction of thromboembolism or underwent preoperative anticoagulation therapy (excluding aspirin); (4) revived ABT intraoperatively or refused ABT perioperatively; (5) did not follow the routine pracices of tranexamic acid and hypotensive anesthesia in our institution: tranexamic acid was given intravenously 2 g 5 min before incision, and administrated 1g 3 and 6 h after the surgery; maintaining the systolic blood pressure at 90-100 mmHg during the operation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| age;sex;Tobacco use;BMI;ASA classification;Crowe classification;Allogeneic RBC transfused;center of rotation height;leg length discrepancy;Length of SSO;reinfusion of ICS;Hb;HCT;PLT;prothrombin time;activated partial thromboplastin time;femoral offset; | — |
Countries
China
Contacts
Public ContactZongke Zhou
Outcome results
None listed